COVID-19: Serial antibody progression in heart transplanted patients after protective vaccination against SARS-Cov-2 coronavirus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024199

Enrollment

600

Registered

2021-02-18

Start date

2021-03-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart transplant U07.1

Interventions

Group 1: Patients after heart transplantation and vaccination receive a questionnaire (mainly questions about the tolerability of the vaccination). In addition, serum for the determination of antibod

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients after heart transplantation and protective vaccination against coronavirus SARS-CoV-2

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The aim is to assess the tolerability and efficacy of the vaccine as well as the antibody progression/immunity after vaccination against SARS-CoV-2 in a collective of heart transplanted patients. It needs to be clarified wheather under chronic immunosuppression a immunity comparable to the normal population can be achieved. In addition, the tolerability and efficacy of the vaccination will be assessed in this previously unstudied population.	—

Measure

Time frame

The aim is to assess the tolerability and efficacy of the vaccine as well as the antibody progression/immunity after vaccination against SARS-CoV-2 in a collective of heart transplanted patients. It needs to be clarified wheather under chronic immunosuppression a immunity comparable to the normal population can be achieved. In addition, the tolerability and efficacy of the vaccination will be assessed in this previously unstudied population.

—

Secondary

Measure	Time frame
Not defined	—

Countries

Germany

Contacts

Public ContactHeike Windhagen

Herz- u. Diabeteszentrum NRW, Klinik für Thorax- u. Kardiovaskularchirurgie

hwindhagen@hdz-nrw.de+49-5731-97-3135

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026